Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

ALGS

Aligos Therapeutics (ALGS)

Aligos Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ALGS
FechaHoraFuenteTítuloSímboloCompañía
05/06/202401:30GlobeNewswire Inc.Aligos Therapeutics Presents Positive Data at the EASL Congress 2024NASDAQ:ALGSAligos Therapeutics Inc
31/05/202415:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
22/05/202415:05GlobeNewswire Inc.Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024NASDAQ:ALGSAligos Therapeutics Inc
21/05/202407:00GlobeNewswire Inc.Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASHNASDAQ:ALGSAligos Therapeutics Inc
07/05/202415:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALGSAligos Therapeutics Inc
07/05/202415:05GlobeNewswire Inc.Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial ResultsNASDAQ:ALGSAligos Therapeutics Inc
30/04/202415:05GlobeNewswire Inc.Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024NASDAQ:ALGSAligos Therapeutics Inc
25/04/202415:05GlobeNewswire Inc.Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 StudyNASDAQ:ALGSAligos Therapeutics Inc
25/04/202407:00GlobeNewswire Inc.Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MDNASDAQ:ALGSAligos Therapeutics Inc
09/04/202407:00GlobeNewswire Inc.Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024NASDAQ:ALGSAligos Therapeutics Inc
03/04/202407:00GlobeNewswire Inc.Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH SubjectsNASDAQ:ALGSAligos Therapeutics Inc
27/03/202407:00GlobeNewswire Inc.Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 StudiesNASDAQ:ALGSAligos Therapeutics Inc
18/03/202407:00GlobeNewswire Inc.Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH SubjectsNASDAQ:ALGSAligos Therapeutics Inc
12/03/202415:05GlobeNewswire Inc.Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALGSAligos Therapeutics Inc
05/03/202415:05GlobeNewswire Inc.Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024NASDAQ:ALGSAligos Therapeutics Inc
04/03/202416:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
26/02/202407:00GlobeNewswire Inc.Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:ALGSAligos Therapeutics Inc
20/02/202407:00GlobeNewswire Inc.Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024NASDAQ:ALGSAligos Therapeutics Inc
13/02/202407:00GlobeNewswire Inc.Aligos Therapeutics Strengthens Finance Leadership Team with Two New AppointmentsNASDAQ:ALGSAligos Therapeutics Inc
30/01/202406:04Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:ALGSAligos Therapeutics Inc
25/01/202405:12Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:ALGSAligos Therapeutics Inc
28/11/202315:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ALGSAligos Therapeutics Inc
17/11/202315:38Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALGSAligos Therapeutics Inc
07/11/202311:03Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ALGSAligos Therapeutics Inc
02/11/202315:08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALGSAligos Therapeutics Inc
02/06/202315:06Edgar (US Regulatory)Revised Proxy Soliciting Materials (definitive) (defr14a)NASDAQ:ALGSAligos Therapeutics Inc
04/05/202315:22Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALGSAligos Therapeutics Inc
04/05/202315:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALGSAligos Therapeutics Inc
28/04/202316:08Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ALGSAligos Therapeutics Inc
28/04/202316:00Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ALGSAligos Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALGS